MRK.N
Latest Trade
88.72USDChange
-0.13(-0.15%)Volume
2,556,228Today's Range
-
89.0052 Week Range
-
89.23As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 88.85 |
|---|---|
Open | 88.99 |
Volume | 2,556,228 |
3M AVG Volume | 180.13 |
Today's High | 89.00 |
Today's Low | 88.21 |
52 Week High | 89.23 |
52 Week Low | 70.89 |
Shares Out (MIL) | 2,545.98 |
Market Cap (MIL) | 226,210.70 |
Forward P/E | 17.20 |
Dividend (Yield %) | 2.75 |
Merck & Co To Acquire Arqule For $20 Per Share In Cash
Lynparza (Olaparib) Approved In China As A First-Line Maintenance Therapy In BRCA-Mutated (BRCAm) Advanced Ovarian Cancer
FDA Grants Priority Review To Merck's Keytruda In Patients With Bladder Cancer
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.
Industry
Biotechnology & Drugs
Executive Leadership
Kenneth C. Frazier
Chairman of the Board, President, Chief Executive Officer
Robert M. Davis
Executive Vice President, Global Services, Chief Financial Officer
Steven C. Mizell
Executive Vice President, Chief Human Resources Officer, Human Resources
Jim Scholefield
Executive Vice President, Chief Information and Digital Officer
Michael T. Nally
Executive Vice President, Chief Marketing Officer
Price To Earnings (TTM) | 23.89 |
|---|---|
Price To Sales (TTM) | 4.92 |
Price To Book (MRQ) | 8.44 |
Price To Cash Flow (TTM) | 16.93 |
Total Debt To Equity (MRQ) | 97.21 |
LT Debt To Equity (MRQ) | 84.50 |
Return on Investment (TTM) | 14.82 |
Return on Equity (TTM) | 11.33 |
* Indexes down: Dow 0.3%, S&P 500 0.22%, Nasdaq 0.26% (Updates to late afternoon)
Merck & Co Inc <MRK.N> said on Monday it would buy ArQule Inc <ARQL.O> for $2.7 billion, as it looks to tap into the drug developer's experimental blood cancer therapy that targets genetic mutations.
Merck & CO said on Monday it would buy cancer drug developer ArQule Inc for $2.7 billion in cash to beef up its portfolio of blood cancer treatments.
AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a form of ovarian cancer.
Merck & Co Inc <MRK.N said on Monday an experimental treatment being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study.
Merck & Co Inc <MRK.N said on Monday an experimental treatment being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study. The drug, vericiguat, reduced the risk of heart failure and hospitalization in patients...
U.S. drugmaker Merck & Co Inc on Monday received approval from the European Commission to market (http://bit.ly/2NZ0QMB) its Ebola vaccine, less than a month after a European medicines panel backed the first-ever vaccine against the deadly virus.
Merck & Co Inc on Monday received approval from the European Commission to market (http://bit.ly/2NZ0QMB) its Ebola vaccine, less than a month after a European medicines panel backed the first-ever vaccine against the deadly virus.
Johnson & Johnson <JNJ.N> said on Thursday it had filed for an approval from European regulators for its two-dose experimental vaccine to protect against Ebola, less than a month after the agency recommended approval of Merck & Co Inc's <MRK.N> vaccine.
A U.S. appeals court on Wednesday dealt a major blow to Merck & Co Inc <MRK.N> as it upheld a ruling that threw out a $2.54 billion jury verdict the drugmaker had won against Gilead Sciences Inc <GILD.O>.
A U.S. appeals court on Wednesday dealt a major blow to Merck & Co Inc as it upheld a ruling that threw out a $2.54 billion jury verdict the drugmaker had won against Gilead Sciences Inc.
The S&P 500 hit a fresh record high on Tuesday, lifted by upbeat earnings from drugmakers Merck and Pfizer, while disappointing quarterly profit from Google-parent Alphabet kept the Nasdaq firmly in the negative territory.
Merck & Co Inc <MRK.N> on Tuesday said it expected immunotherapy Keytruda to continue its market dominance as an initial treatment for advanced lung cancer as sales of the drug topped $3 billion (£2.3 billion) in a quarter for the first time, beating lofty Wall Street estimates...
Wall Street opened slightly lower on Tuesday as investors assessed a mixed batch of earnings reports, including from Google-parent Alphabet and big drugmakers Merck and Pfizer.
Merck & Co Inc said on Tuesday it intends to ramp up production of its top-selling vaccine Gardasil in 2023 and warned of a slowdown in revenue growth next year as demand for the therapy outpaces supply.
* WORLD HEALTH ORGANIZATION SAYS "WELCOMES" THE EMA ANNOUNCEMENT RECOMMENDING A CONDITIONAL MARKETING AUTHORIZATION FOR MERCK'S V920 EBOLA ZAIRE VACCINE
The world's first Ebola vaccine was recommended for approval by European drugs regulators on Friday in a move hailed by the World Health Organization (WHO) as a "triumph for public health" that would save many lives.
A panel of the European drugs regulator on Friday recommended approving Merck & Co's vaccine for the deadly Ebola virus.
* Apple up on JPM's iPhone volume forecast raise, Cook's comments
AstraZeneca Plc <AZN.L> and Merck & Co Inc <MRK.N> said on Monday their treatment for newly diagnosed advanced ovarian
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.